ALVO

Alvotech is a biotech company specializing in the development and manufacturing of biosimilar medicines for global markets. Headquartered in Reykjavik, Iceland, the company operates state-of-the-art manufacturing facilities in Iceland and maintains research and development operations across multiple locations. Alvotech focuses on creating biosimilar versions of complex biologic drugs used to treat conditions including autoimmune diseases, eye disorders, and bone loss. The company's pipeline includes biosimilar candidates referencing major biologics such as Stelara, Prolia, Eylea, and Simponi, among others. Alvotech employs approximately 800 people globally and has established strategic partnerships with major pharmaceutical companies including Teva Pharmaceutical Industries for commercialization and distribution in various markets. The company completed its business combination with Oaktree Acquisition Corp II and began trading on NASDAQ in June 2022. Alvotech received its first commercial approval for AVT02, a biosimilar to Humira, in 2023, marking a significant milestone as it transitions from a development-stage company to a commercial operation. The company operates an integrated business model that encompasses the entire value chain from development through manufacturing and regulatory approval, positioning itself as a vertically integrated biosimilar developer with capabilities to serve both developed and emerging markets worldwide.